In Q4, 2021 Galapagos biopharma received approval for Jyseleca® for the treatment of adult patients with moderately to severely active ulcerative colitis (UC). The IBD conference in Malmö, Sweden created the first significant opportunity to discuss and present the key benefits of Jyseleca to Healthcare Providers from across the Nordic region at single venue.
The IBD conference was attended by over 300 delegates from Sweden, Norway, Denmark and Finland and Galapagos wanted to outshine its competitors by not only have a higher share of voice, but by also delivering highly memorable activities at the event. W was asked to support Galapagos achieve this, from the booth design to identifying activities to increase attendance to the company sponsored symposium.
W put together an extensive smorgasbord of activities that we felt would ensure that Jyseleca would be top of mind for the delegates attending the conference. Our suggestion ranged from an impactful Jyseleca branded congress booth to activities to attract delegates to the booth and symposium, to supporting speakers with their symposium presentations, to a symposium invitation, to a Jyseleca promotional film, and to a film promoting the topics at the company sponsored symposium.
